Logo image of ZVRA

ZEVRA THERAPEUTICS INC (ZVRA) Stock Fundamental Analysis

NASDAQ:ZVRA - Nasdaq - US4884452065 - Common Stock - Currency: USD

7.68  -0.15 (-1.92%)

After market: 7.68 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ZVRA. ZVRA was compared to 193 industry peers in the Pharmaceuticals industry. ZVRA has a bad profitability rating. Also its financial health evaluation is rather negative. ZVRA is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ZVRA has reported negative net income.
In the past year ZVRA has reported a negative cash flow from operations.
ZVRA had negative earnings in each of the past 5 years.
In the past 5 years ZVRA reported 4 times negative operating cash flow.
ZVRA Yearly Net Income VS EBIT VS OCF VS FCFZVRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M

1.2 Ratios

The Return On Assets of ZVRA (-44.34%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -121.72%, ZVRA is doing worse than 62.16% of the companies in the same industry.
Industry RankSector Rank
ROA -44.34%
ROE -121.72%
ROIC N/A
ROA(3y)-36.67%
ROA(5y)-91.49%
ROE(3y)-57.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZVRA Yearly ROA, ROE, ROICZVRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

ZVRA has a Gross Margin of 53.72%. This is in the better half of the industry: ZVRA outperforms 63.24% of its industry peers.
The Profit Margin and Operating Margin are not available for ZVRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZVRA Yearly Profit, Operating, Gross MarginsZVRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

3

2. Health

2.1 Basic Checks

ZVRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZVRA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ZVRA has more shares outstanding
ZVRA has a worse debt/assets ratio than last year.
ZVRA Yearly Shares OutstandingZVRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ZVRA Yearly Total Debt VS Total AssetsZVRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -2.36, we must say that ZVRA is in the distress zone and has some risk of bankruptcy.
ZVRA has a Altman-Z score (-2.36) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.84 indicates that ZVRA is somewhat dependend on debt financing.
ZVRA's Debt to Equity ratio of 0.84 is on the low side compared to the rest of the industry. ZVRA is outperformed by 71.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Altman-Z -2.36
ROIC/WACCN/A
WACC9.47%
ZVRA Yearly LT Debt VS Equity VS FCFZVRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.88 indicates that ZVRA has no problem at all paying its short term obligations.
ZVRA has a Current ratio (2.88) which is comparable to the rest of the industry.
A Quick Ratio of 2.88 indicates that ZVRA has no problem at all paying its short term obligations.
With a Quick ratio value of 2.88, ZVRA perfoms like the industry average, outperforming 52.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.88
ZVRA Yearly Current Assets VS Current LiabilitesZVRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

ZVRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -71.30%.
Looking at the last year, ZVRA shows a very strong growth in Revenue. The Revenue has grown by 49.58%.
Measured over the past years, ZVRA shows a very strong growth in Revenue. The Revenue has been growing by 27.37% on average per year.
EPS 1Y (TTM)-71.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.5%
Revenue 1Y (TTM)49.58%
Revenue growth 3Y27.37%
Revenue growth 5YN/A
Sales Q2Q%27.63%

3.2 Future

ZVRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.09% yearly.
The Revenue is expected to grow by 68.19% on average over the next years. This is a very strong growth
EPS Next Y-57%
EPS Next 2Y31.73%
EPS Next 3Y37.64%
EPS Next 5Y35.09%
Revenue Next Year-21.03%
Revenue Next 2Y84.28%
Revenue Next 3Y88.74%
Revenue Next 5Y68.19%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ZVRA Yearly Revenue VS EstimatesZVRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
ZVRA Yearly EPS VS EstimatesZVRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -20 -40 -60 -80 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZVRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZVRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZVRA Price Earnings VS Forward Price EarningsZVRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZVRA Per share dataZVRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ZVRA's earnings are expected to grow with 37.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.73%
EPS Next 3Y37.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZVRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZEVRA THERAPEUTICS INC

NASDAQ:ZVRA (2/21/2025, 8:00:02 PM)

After market: 7.68 0 (0%)

7.68

-0.15 (-1.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)02-28 2025-02-28/amc
Inst Owners62.6%
Inst Owner ChangeN/A
Ins Owners6.34%
Ins Owner Change54.23%
Market Cap409.96M
Analysts84.29
Price Target22.15 (188.41%)
Short Float %11.28%
Short Ratio12.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-34.51%
Min EPS beat(2)-60.59%
Max EPS beat(2)-8.43%
EPS beat(4)1
Avg EPS beat(4)-24.3%
Min EPS beat(4)-60.59%
Max EPS beat(4)17.96%
EPS beat(8)2
Avg EPS beat(8)-20.29%
EPS beat(12)3
Avg EPS beat(12)-21.21%
EPS beat(16)4
Avg EPS beat(16)-31.48%
Revenue beat(2)1
Avg Revenue beat(2)-12.73%
Min Revenue beat(2)-25.59%
Max Revenue beat(2)0.14%
Revenue beat(4)2
Avg Revenue beat(4)-6.46%
Min Revenue beat(4)-25.59%
Max Revenue beat(4)10.39%
Revenue beat(8)4
Avg Revenue beat(8)13.66%
Revenue beat(12)6
Avg Revenue beat(12)9.01%
Revenue beat(16)8
Avg Revenue beat(16)35.98%
PT rev (1m)3.4%
PT rev (3m)3.4%
EPS NQ rev (1m)3.22%
EPS NQ rev (3m)-88.02%
EPS NY rev (1m)0.29%
EPS NY rev (3m)-18.79%
Revenue NQ rev (1m)2.36%
Revenue NQ rev (3m)-43.05%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)-12.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.54
P/FCF N/A
P/OCF N/A
P/B 5.88
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.97
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-1.3
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS0.46
BVpS1.31
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.34%
ROE -121.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.72%
FCFM N/A
ROA(3y)-36.67%
ROA(5y)-91.49%
ROE(3y)-57.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.38%
Cap/Sales 0.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 2.88
Altman-Z -2.36
F-Score2
WACC9.47%
ROIC/WACCN/A
Cap/Depr(3y)25.82%
Cap/Depr(5y)19.71%
Cap/Sales(3y)0.76%
Cap/Sales(5y)0.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.5%
EPS Next Y-57%
EPS Next 2Y31.73%
EPS Next 3Y37.64%
EPS Next 5Y35.09%
Revenue 1Y (TTM)49.58%
Revenue growth 3Y27.37%
Revenue growth 5YN/A
Sales Q2Q%27.63%
Revenue Next Year-21.03%
Revenue Next 2Y84.28%
Revenue Next 3Y88.74%
Revenue Next 5Y68.19%
EBIT growth 1Y-103.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-86.53%
EBIT Next 3Y37.49%
EBIT Next 5Y49.32%
FCF growth 1Y-358.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-360.42%
OCF growth 3YN/A
OCF growth 5YN/A